Scleroderma associated with ANCA-associated vasculitis

Hee Rho Young, Jae Choi Seong, Young Ho Lee, Jong Dae Ji, Gwan Gyu Song

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

We have recently reported on two cases of scleroderma patients with ANCA-associated vasculitis for the first time in Korea. In order to explore the nature of this disease combination, we pooled together all the previously known cases and statistically analyzed them. Out of the 50 selected cases, survival analysis was done for comparison of the scleroderma disease period and the clinical factors associated with ANCA-associated vasculitis (AAV). Kaplan-Meier analysis revealed that patients having anti-topoisomerase antibody (anti-Scl-70) and, probably, PR-3 ANCA are at a higher risk for developing AAV than patients without both anti-topoisomerase antibody and anti-centromere antibody (ACA), and patients with MPO-ANCA. Multivariate Cox regression analysis revealed having anti-topoisomerase antibody as a risk factor for developing AAV [OR 3.1 (95% CI 1.11-8.55), P = 0.031]. We suggest that having anti-topoisomerase antibodies may play a role among scleroderma patients in developing AAV.

Original languageEnglish
Pages (from-to)369-375
Number of pages7
JournalRheumatology International
Volume26
Issue number5
DOIs
Publication statusPublished - 2006 Mar 1

Fingerprint

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Anti-Idiotypic Antibodies
Antineutrophil Cytoplasmic Antibodies
Centromere
Kaplan-Meier Estimate
Survival Analysis
Korea
Regression Analysis

Keywords

  • ANCA
  • Scleroderma
  • Vasculitis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Scleroderma associated with ANCA-associated vasculitis. / Young, Hee Rho; Seong, Jae Choi; Lee, Young Ho; Ji, Jong Dae; Song, Gwan Gyu.

In: Rheumatology International, Vol. 26, No. 5, 01.03.2006, p. 369-375.

Research output: Contribution to journalReview article

@article{5a80275a6f324a62b0780e3223b56aa2,
title = "Scleroderma associated with ANCA-associated vasculitis",
abstract = "We have recently reported on two cases of scleroderma patients with ANCA-associated vasculitis for the first time in Korea. In order to explore the nature of this disease combination, we pooled together all the previously known cases and statistically analyzed them. Out of the 50 selected cases, survival analysis was done for comparison of the scleroderma disease period and the clinical factors associated with ANCA-associated vasculitis (AAV). Kaplan-Meier analysis revealed that patients having anti-topoisomerase antibody (anti-Scl-70) and, probably, PR-3 ANCA are at a higher risk for developing AAV than patients without both anti-topoisomerase antibody and anti-centromere antibody (ACA), and patients with MPO-ANCA. Multivariate Cox regression analysis revealed having anti-topoisomerase antibody as a risk factor for developing AAV [OR 3.1 (95{\%} CI 1.11-8.55), P = 0.031]. We suggest that having anti-topoisomerase antibodies may play a role among scleroderma patients in developing AAV.",
keywords = "ANCA, Scleroderma, Vasculitis",
author = "Young, {Hee Rho} and Seong, {Jae Choi} and Lee, {Young Ho} and Ji, {Jong Dae} and Song, {Gwan Gyu}",
year = "2006",
month = "3",
day = "1",
doi = "10.1007/s00296-005-0011-5",
language = "English",
volume = "26",
pages = "369--375",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Scleroderma associated with ANCA-associated vasculitis

AU - Young, Hee Rho

AU - Seong, Jae Choi

AU - Lee, Young Ho

AU - Ji, Jong Dae

AU - Song, Gwan Gyu

PY - 2006/3/1

Y1 - 2006/3/1

N2 - We have recently reported on two cases of scleroderma patients with ANCA-associated vasculitis for the first time in Korea. In order to explore the nature of this disease combination, we pooled together all the previously known cases and statistically analyzed them. Out of the 50 selected cases, survival analysis was done for comparison of the scleroderma disease period and the clinical factors associated with ANCA-associated vasculitis (AAV). Kaplan-Meier analysis revealed that patients having anti-topoisomerase antibody (anti-Scl-70) and, probably, PR-3 ANCA are at a higher risk for developing AAV than patients without both anti-topoisomerase antibody and anti-centromere antibody (ACA), and patients with MPO-ANCA. Multivariate Cox regression analysis revealed having anti-topoisomerase antibody as a risk factor for developing AAV [OR 3.1 (95% CI 1.11-8.55), P = 0.031]. We suggest that having anti-topoisomerase antibodies may play a role among scleroderma patients in developing AAV.

AB - We have recently reported on two cases of scleroderma patients with ANCA-associated vasculitis for the first time in Korea. In order to explore the nature of this disease combination, we pooled together all the previously known cases and statistically analyzed them. Out of the 50 selected cases, survival analysis was done for comparison of the scleroderma disease period and the clinical factors associated with ANCA-associated vasculitis (AAV). Kaplan-Meier analysis revealed that patients having anti-topoisomerase antibody (anti-Scl-70) and, probably, PR-3 ANCA are at a higher risk for developing AAV than patients without both anti-topoisomerase antibody and anti-centromere antibody (ACA), and patients with MPO-ANCA. Multivariate Cox regression analysis revealed having anti-topoisomerase antibody as a risk factor for developing AAV [OR 3.1 (95% CI 1.11-8.55), P = 0.031]. We suggest that having anti-topoisomerase antibodies may play a role among scleroderma patients in developing AAV.

KW - ANCA

KW - Scleroderma

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=33644629873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644629873&partnerID=8YFLogxK

U2 - 10.1007/s00296-005-0011-5

DO - 10.1007/s00296-005-0011-5

M3 - Review article

VL - 26

SP - 369

EP - 375

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 5

ER -